Brokerages forecast that LifePoint Health (NASDAQ:LPNT) will post sales of $1.61 billion for the current fiscal quarter, according to Zacks. Nine analysts have issued estimates for LifePoint Health’s earnings, with the lowest sales estimate coming in at $1.60 billion and the highest estimate coming in at $1.64 billion. LifePoint Health reported sales of $1.63 billion during the same quarter last year, which would suggest a negative year-over-year growth rate of 1.2%. The firm is scheduled to report its next earnings results on Friday, April 27th.
According to Zacks, analysts expect that LifePoint Health will report full year sales of $6.38 billion for the current financial year, with estimates ranging from $6.31 billion to $6.41 billion. For the next fiscal year, analysts forecast that the company will report sales of $6.52 billion per share, with estimates ranging from $6.43 billion to $6.59 billion. Zacks’ sales averages are an average based on a survey of analysts that follow LifePoint Health.
LifePoint Health (NASDAQ:LPNT) last announced its quarterly earnings data on Friday, February 23rd. The company reported $0.77 earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.81 by ($0.04). The firm had revenue of $1.49 billion during the quarter, compared to the consensus estimate of $1.58 billion. LifePoint Health had a net margin of 1.46% and a return on equity of 6.34%. The firm’s quarterly revenue was down 7.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.07 earnings per share.
LPNT has been the subject of several research analyst reports. BidaskClub raised LifePoint Health from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Robert W. Baird restated a “buy” rating and issued a $54.00 target price on shares of LifePoint Health in a research note on Tuesday, March 27th. Morgan Stanley restated an “equal weight” rating and issued a $46.00 target price (down from $50.00) on shares of LifePoint Health in a research note on Monday, February 26th. SunTrust Banks decreased their target price on LifePoint Health to $44.00 and set a “hold” rating for the company in a research note on Monday, February 26th. Finally, ValuEngine downgraded LifePoint Health from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. One research analyst has rated the stock with a sell rating, thirteen have given a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $54.31.
LifePoint Health stock traded up $0.05 during midday trading on Monday, hitting $49.55. The stock had a trading volume of 23,944 shares, compared to its average volume of 545,799. The company has a quick ratio of 1.49, a current ratio of 1.70 and a debt-to-equity ratio of 1.26. The firm has a market cap of $1,907.96, a P/E ratio of 13.60, a P/E/G ratio of 1.49 and a beta of 0.50. LifePoint Health has a 12 month low of $41.45 and a 12 month high of $67.95.
In other LifePoint Health news, Chairman William F. Carpenter III acquired 21,368 shares of LifePoint Health stock in a transaction dated Wednesday, February 28th. The stock was acquired at an average cost of $46.80 per share, for a total transaction of $1,000,022.40. Following the completion of the transaction, the chairman now owns 482,668 shares in the company, valued at approximately $22,588,862.40. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 8.76% of the company’s stock.
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Alliancebernstein L.P. lifted its position in LifePoint Health by 1.7% in the fourth quarter. Alliancebernstein L.P. now owns 1,762,076 shares of the company’s stock worth $87,751,000 after purchasing an additional 28,721 shares during the period. Boston Partners lifted its position in LifePoint Health by 50.8% in the fourth quarter. Boston Partners now owns 874,690 shares of the company’s stock worth $43,559,000 after purchasing an additional 294,480 shares during the period. JPMorgan Chase & Co. lifted its position in LifePoint Health by 26.4% in the third quarter. JPMorgan Chase & Co. now owns 132,589 shares of the company’s stock worth $7,757,000 after purchasing an additional 27,726 shares during the period. New York State Common Retirement Fund lifted its position in LifePoint Health by 3.2% in the third quarter. New York State Common Retirement Fund now owns 84,969 shares of the company’s stock worth $4,920,000 after purchasing an additional 2,669 shares during the period. Finally, First Trust Advisors LP lifted its position in LifePoint Health by 33.4% in the fourth quarter. First Trust Advisors LP now owns 414,248 shares of the company’s stock worth $20,630,000 after purchasing an additional 103,680 shares during the period.
About LifePoint Health
LifePoint Health, Inc, through its subsidiaries, owns and operates community hospitals, regional health systems, physician practices, outpatient centers, and post-acute facilities in the United States. Its hospitals provide a range of medical and surgical services, such as general surgery, internal medicine, obstetrics, emergency room care, radiology, oncology, diagnostic care, coronary care, rehabilitation, and pediatric, as well as specialized services, including open-heart surgery, skilled nursing, psychiatric care, and neuro-surgery.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LifePoint Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LifePoint Health and related companies with MarketBeat.com's FREE daily email newsletter.